Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding    RO   CH0012032113


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Roche : Changes in Roche's Board of Directors and Corporate Executive Committee

share with twitter share with LinkedIn share with facebook
share via e-mail
06/12/2019 | 12:37pm EDT

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Peter Voser (61), a member of the Board of Directors of Roche Holding Ltd since 2011, has decided to step down as a member of the Board of Directors of Roche at the end of June 2019 due to his additional role as interim CEO of ABB.

Roche Chairman Christoph Franz: "Peter Voser has made important contributions to Roche's success as a member of the Board and the Compensation Committee. On behalf of the Board of Directors of Roche, I would like to thank him most sincerely for his contribution.

At the same time Roche announced the following changes to the Corporate Executive Committee:

Michael Heuer (65), CEO Roche Diagnostics and member of the Corporate Executive Committee, will retire as planned at the end of July. The Board of Directors has appointed Thomas Schinecker (44), currently Head of Centralised and Point of Care Solutions, as CEO Roche Diagnostics and a member of the Corporate Executive Committee with effect from 1 August 2019.

Stephan Feldhaus (57), Head of Group Communications and member of Roches enlarged Corporate Executive Committee, has decided to continue his career outside the company as of the end of September 2019. He will be succeeded on 1 October 2019 by Barbara Schdler (57), currently Head of Communications and Public Affairs at E.ON SE. Barbara Schdler will report to CEO Severin Schwan as a member of the enlarged Corporate Executive Committee.

Severin Schwan: "Michael Heuer joined Roche following the acquisition of Boehringer Mannheim in 1998 and, after a long and distinguished career, has played a key role in making our company the world's leading provider of diagnostic solutions. We are extremely grateful to him for his personal contribution". Schwan added: "I am delighted that we have been able to appoint Thomas Schinecker, an internal successor with a strong track record, as the new CEO for our Diagnostics Division. Thomas Schinecker has broad and international experience in our business".

Severin Schwan continued: "Stephan Feldhaus has shaped our communications over the past ten years and made a significant contribution to the positive reputation of our company. I thank him very much for his valuable contribution and wish him all the best. I am pleased that we have Barbara Schdler joining Roche as his successor. She has worked successfully for many years as a communications executive in global private companies and in the public sector".

Michael Heuer joined Boehringer Mannheim in 1983 and was appointed to his current position in 2018. Following the acquisition of Boehringer Mannheim by Roche in 1998, he held various management positions in sales, marketing and product development in Germany, Austria and the United States before being appointed Head of Roche's Near Patient Testing business unit. Prior to his current role, he was Head of Diagnostics Europe, Middle East, Africa and Latin America region. Michael Heuer holds a PhD in Chemistry from the University of Kiel.

Thomas Schinecker began his career in 2003 as a trainee for Roche Diagnostics under the Roche Perspectives programme. He has held various management positions in marketing & sales and product development in Singapore, Austria, Sweden and the United States. Before assuming his current position as Head of the Global Business Area Centralised and Point of Care Solutions based in Rotkreuz, Switzerland, he was General Manager for Roche Diagnostics Germany. Thomas Schinecker holds a PhD in Molecular Biology from New York University, USA.

Stephan Feldhaus joined Roche in 2010 as Head of Group Communications and is a member of the enlarged Corporate Executive Committee, where he has since been responsible for the Group's internal and external communications. He previously held various management positions in communications at Siemens and worked as a social ethicist and theologian. He received his doctorate in theology from the University of Munich.

Barbara Schdler's previous career as communications manager included positions at E.ON SE, Lufthansa, SAP and the German Federal Ministry of Finance. She holds a Master's degree in Economics from the Johannes Gutenberg University of Mainz.

(c) NNA 2019 LEBANON Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
E.ON SE 0.36% 9.45 Delayed Quote.9.54%
ROCHE HOLDING -2.36% 265 Delayed Quote.13.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING
07/19REMINDER : Invitation to Roche's Half Year Results 2019 Thursday, 25 July 2019 &..
07/16Abbott to hike production of lower-cost glucose monitors as diabetes soars
07/10CHUGAI PHARMACEUTICAL : Further Clinical Data including Long-Term Follow-up for ..
07/10ROCHE : Genentech Presents a Broad Range of Data for Hemlibra Demonstrating Cont..
07/04ROCHE : Genentech Announces Positive Results for First Global Phase III Study In..
07/03ROCHE : announces positive results for first global phase III study investigatin..
07/02Foundation Medicine Expands Indication for FoundationOne®CDx as a Companion ..
07/01ROCHE : CHMP recommends EU approval of Roche's Tecentriq in combination with Abr..
06/28ROCHE : CHMP recommends EU approval of Roche's Tecentriq in combination with Abr..
06/28CHUGAI PHARMACEUTICAL : Obtains Approval of FoundationOne CDx Cancer Genomic Pro..
More news
Financials (CHF)
Sales 2019 60 696 M
EBIT 2019 22 027 M
Net income 2019 14 090 M
Debt 2019 2 214 M
Yield 2019 3,37%
P/E ratio 2019 19,4x
P/E ratio 2020 19,0x
EV / Sales2019 3,76x
EV / Sales2020 3,66x
Capitalization 226 B
Duration : Period :
Roche Holding Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 289,50  CHF
Last Close Price 265,00  CHF
Spread / Highest target 16,6%
Spread / Average Target 9,25%
Spread / Lowest Target 1,89%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING13.37%230 263
JOHNSON & JOHNSON2.34%345 980
PFIZER-1.35%237 451
ROCHE HOLDING LTD.11.42%230 263
NOVARTIS24.46%216 273